Shares of Mallinckrodt PLC (NYSE MNK) opened at 44.51 on Friday. About 2.00 million shares traded. The value of the investment in (MNK) increased from $7,125,000 to $7,521,000 a change of $396,000 quarter over quarter.
A number of other large investors also recently added to or reduced their stakes in MNK. Wells Fargo & Company MN now owns 164,309 shares of the company's stock valued at $7,322,000 after buying an additional 14,485 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Mallinckrodt PLC by 1,455.5% in the first quarter. Vanguard Group Inc. now owns 10,247,891 shares of the company's stock valued at $456,748,000 after buying an additional 103,924 shares during the period. LS Investment Advisors LLC increased its stake in shares of Mallinckrodt PLC by 18.5% in the first quarter. BlackRock Inc. now owns 8,734,709 shares of the company's stock worth $389,307,000 after buying an additional 8,524,773 shares during the period. Ameritas Investment Partners Inc. purchased a new position in Mallinckrodt PLC during the first quarter valued at $115,000. Elm Ridge Management Llc who had been investing in Mbia Inc for a number of months, seems to be bullish on the $1.28B market cap company. $50,466 worth of Mallinckrodt PLC (NYSE:MNK) shares were bought by Trudeau Mark.
The share price of Mallinckrodt plc (NYSE:MNK) was down -6.69% during the last trading session, with a day high of 40.83.
The company's Average Earnings Estimate for the Current Fiscal quarter is $1.96, according to consensus of 15 analysts. The stock of Mallinckrodt PLC (NYSE:MNK) earned "Outperform" rating by Leerink Swann on Wednesday, October 7. The business had revenue of $824.50 million for the quarter, compared to analyst estimates of $829.56 million. The institutional investor held 84,599 shares of the major pharmaceuticals company at the end of 2016Q4, valued at $4.22M, down from 212,299 at the end of the previous reported quarter. The business's quarterly revenue was down 4.9% on a year-over-year basis.
COPYRIGHT VIOLATION NOTICE: "Mallinckrodt PLC (NYSE:MNK) Given a $56.00 Price Target by Deutsche Bank AG Analysts" was reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another domain, it was illegally stolen and republished in violation of global copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/09/mallinckrodt-plc-mnk-given-a-87-00-price-target-by-canaccord-genuity-analysts.html. Piper Jaffray Companies set a $85.00 price target on Mallinckrodt PLC and gave the company a buy rating in a research note on Sunday, July 16th. Oppenheimer Holdings, Inc. set a $70.00 price objective on Mallinckrodt PLC and gave the company a buy rating in a report on Friday, July 28th.
BBCI: Rafa Marquez: Mexico footballer accused of cartel link
His American assets have been frozen, and American citizens and companies are now forbidden from doing business with him. He co-founded the Cartel Chronicles project with Brandon Darby and Stephen K.
11/18/2016 - Mallinckrodt plc had its "buy" rating reiterated by analysts at Deutsche Bank. Jefferies Group LLC reissued a buy rating and issued a $70.00 price objective on shares of Mallinckrodt PLC in a report on Friday, April 21st.
Several other equities analysts have also recently weighed in on the company. The company presently has an average rating of "Buy" and a consensus target price of $74.09.
In related news, VP Coleman N. Lannum III purchased 1,350 shares of the business's stock in a transaction on Friday, June 2nd. Following the transaction, the vice president now owns 30,955 shares in the company, valued at $1,327,659.95. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The stock was acquired at an average cost of $40.24 per share, with a total value of $40,240.00. The disclosure for this purchase can be found here. Insiders have acquired 5,818 shares of company stock worth $248,608 in the last quarter. Company insiders own 0.53% of the company's stock.
Mallinckrodt public limited company, launched on January 9, 2013, develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
- Rory to go with three wedge setup, add 3-iron for PGA
- 'Natasha, Pierre & the Great Comet of 1812' to Close on Broadway
- Forfait pour Cincinnati, Murray perd sa place de numéro un mondial — ATP
- Insider Trading at Independence Realty Trust Inc.?
- PSG to Offer Arsenal £80 Million for Alexis Sanchez
- Houghton Mifflin Harcourt Company (NASDAQ:HMHC) Receives Hold Rating from Stifel Nicolaus
- Tejashwi launches agitation against Nitish for 'insulting' mandate
- Barcelona raises Coutinho offer as Liverpool star pushes for move
- The Goodyear Tire & Rubber Company - GT - Stock Price Today
- Golden buzzer for Flint's Johnny Manuel on 'America's Got Talent'